Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

9.50
-0.5500-5.47%
Volume:682.01K
Turnover:6.62M
Market Cap:795.79M
PE:-15.19
High:10.03
Open:9.99
Low:9.46
Close:10.05
52wk High:26.95
52wk Low:6.39
Shares:83.77M
Float Shares:74.12M
Volume Ratio:1.10
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6252
EPS(LYR):-0.5320
ROE:-35.43%
ROA:-21.66%
PB:3.53
PE(LYR):-17.86

Loading ...

Corvus Pharmaceuticals Currently Down Eight Days Straight, on Track for Longest Losing Streak Since February 2025

Dow Jones
·
Oct 09

Corvus announces initiation of Phase 1b clinical trial of soquelitinib

TIPRANKS
·
Oct 01

Corvus Starts Phase 1b Trial of Soquelitinib in Hidradenitis Suppurativa Patients

Reuters
·
Oct 01

Corvus Pharmaceuticals, - Primary Endpoint is Safety and Tolerability; Key Efficacy Endpoint is Hiscr 50/75 at Week 12

THOMSON REUTERS
·
Oct 01

Corvus Pharmaceuticals Announces Initiation of Phase 1B Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

THOMSON REUTERS
·
Oct 01

Corvus Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Does Peer-Reviewed Phase 1 Soquelitinib Data Reshape The Bull Case For Corvus Pharmaceuticals (CRVS)?

Simply Wall St.
·
Aug 29

Corvus Publishes Final Phase 1/1b Soquelitinib Data in Blood Supporting Phase 3 Relapsed/refractory PTCL Trial

Reuters
·
Aug 27

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1B T Cell Lymphoma Trial

THOMSON REUTERS
·
Aug 27

Barclays Keeps Their Buy Rating on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
Aug 07

Corvus Publishes Corporate Presentation Highlighting Soquelitinib ITK Inhibitor Pipeline in Immune Disease and T-Cell Malignancies

Reuters
·
Aug 07

Corvus Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate

Benzinga Earnings
·
Aug 07

Corvus Pharmaceuticals Schedules Q2 Financial Results Conference Call and Webcast

Reuters
·
Jul 31

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

THOMSON REUTERS
·
Jul 31

Corvus Pharmaceuticals Director Ian T. Clark Resigns from Board

Reuters
·
Jul 23

Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), IN8bio (INAB)

TIPRANKS
·
Jul 06

Top Corvus Pharmaceuticals Insider Makes Bold New Bet on the Company’s Future

TIPRANKS
·
Jun 16

Corvus Pharma director David Scott Moore acquires 21,700 common shares for $250,236.72

Reuters
·
Jun 16

Corvus Pharmaceuticals (CRVS) Is Up 7.3% After Promising Soquelitinib Data And Extended Cash Runway

Simply Wall St.
·
Jun 15